2014 Immunochemistry & Immunobiology Gordon Research Conference & Gordon Research

2014年免疫化学和免疫生物学戈登研究会议（GRC）将聚集31名特邀演讲者和165名与会者，为期四天半，以考虑和讨论最近获得的免疫学数据，但重点关注九个具有深刻生物学和临床相关性的主题。特别是，2014年GRC将考虑越来越多的证据表明，免疫细胞和分子对基础病理生理学领域做出了至关重要的、迄今为止未曾预料到的贡献，如代谢调节，远远超出了对感染的反应。此外，2014年GRC将与炎症，过敏和癌症的新型免疫治疗剂的功效激增以及疫苗研究的新成功相吻合。在这些背景下，2014年GRC的目标无非是对免疫学的基础研究优先事项，一般奖学金和翻译潜力进行社区范围的重新评估。这些目标可以通过一个密集的会议来实现，利用年龄，性别和种族的全方位;足够大的规模来捕捉相关的专业知识，但足够小，以促进互动和话语：这是免疫化学和免疫生物学的GRC的标志，即将进入第48个年头。为了给2014年GRC实现其目标的每一个机会，它将由第一次免疫学戈登研究研讨会（GRS）之前，一个为期一天半的会议，旨在准备50名年轻的研究人员参加GRC，在一个合议，同行领导的环境。GRS将不仅仅是加强2014年的GRC，而是特别旨在为下一代提供鼓舞人心的培训体验。 2014年GRC/GRS的教师必须反映所有参与者的愿望和机会。因此，所有受邀演讲者都是各自领域公认的或新兴的领导者，具有公认的沟通和激励能力，并代表整个社区，包括非洲研究人员。会议主持人，其中75%是妇女，将结合具体情况，促进对每次发言的讨论。会议场地配备了最先进的视听设施，并提供公共餐饮和休闲活动。但是，它也足够远，以劝阻参与者离开现场。 2014年GRC将继续保持卓越的传统，因此被广泛认为，受邀者，尽管是在他们的领域最繁忙的，迅速承诺参加至少3天。2014年的GRC也将是创新的。除了在免疫学上第一个提供GRS外，还根据对以前会议的评估进行了其他改进。事实上，2014年全球资源中心/全球资源战略将包括经过验证的创新成果分析。2010年和2012年的会议获得了NIH的资助，并从提交评估的95%的参与者中获得了最高的评级。因此，有充分的理由相信，对2014年全球资源中心的投资将是富有成效的。

DESCRIPTION (provided by applicant): The 2014 Gordon Research Conference (GRC) in Immunochemistry and Immunobiology will assemble 31 invited speakers and 165 participants for four and a half days, to consider and discuss the most recently obtained data across the breadth of immunology but focused on nine topical themes of profound biological and clinical relevance. In particular, the 2014 GRC will consider growing evidence that immune cells and molecules make critical, hitherto unanticipated contributions to areas of fundamental pathophysiology, such as metabolic regulation, that extend well beyond responses to infection. Additionally, the 2014 GRC will coincide with a surging tide of efficacy of new classes of immuno-therapeutics in inflammation, allergy, and cancer, and with new successes in vaccine research. In these contexts, the 2014 GRC aims for nothing less than a community-wide re-assessment of basic research priorities, general scholarship, and translational potentials in immunology. These aims can be achieved by an intensive conference, drawing on the full spectrum of age, gender, and ethnicity; of large enough size to capture relevant expertise, but small enough to promote interaction and discourse: such is the hallmark of the GRC in Immunochemistry and Immunobiology, soon to enter its 48th year. To give the 2014 GRC every chance of achieving its goals, it will be preceded by the first immunology Gordon Research Seminar (GRS), a one and one half day meeting that aims to prepare 50 young researchers for participation in the GRC, in a collegial, peer-led environment. The GRS will not simply enhance the 2014 GRC, but specifically aims to provide an inspirational training experience for the next generation. The faculty for the 2014 GRC/GRS must reflect aspiration and opportunity for all participants. Thus, all invited speakers are acknowledged or emerging leaders in their fields, with proven capacity to communicate and motivate, and who collectively represent the whole community, including a specific inclusion of African researchers. Session-leads, of whom 75% will be women, will contextualize and promote discussion of each presentation. The conference site is equipped with state-of-the-art audio-visual facilities and offers communal dining and relaxation activities. But, it is also sufficiently remote to dissuade participants from leaving th site. The 2014 GRC will continue a tradition of excellence, so widely perceived that invitees, despite being among the busiest in their field, have promptly committed to attending for at least 3 days. The 2014 GRC will also be innovative. As well as being the first in immunology to offer a GRS, other refinements have been made in response to evaluation of preceding conferences. Indeed, the 2014 GRC/GRS will include proven and innovative outcomes analysis. The 2010 and 2012 meetings received NIH funding, and earned the highest possible rating from most of the 95% of participants who submitted evaluations. There are therefore good grounds to believe that investment in the 2014 GRC will be highly productive.